Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNASE1 | P07998 | 1/20 | 0.39 |
| ▸ | TK2 | O00142 | 7/20 | 0.38 |
| ▸ | TK1 | P04183 | 9/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6756344 | 0.94 | RNASE1 (0.37) | RNASE1TK2TK1HPGD | |
| SCHEMBL7908351 | 0.91 | TK2 (0.35) | RNASE1TK2TK1 | |
| SCHEMBL3612842 | 0.90 | PYGM (0.38) | RNASE1TK2TK1 | |
| SCHEMBL29414069 | 0.90 | LMNA (0.37) | RNASE1 | |
| SCHEMBL1705943 | 0.87 | TK1 (0.35) | TK2TK1HPGD | |
| SCHEMBL7640426 | 0.87 | RNASE1 (0.39) | RNASE1TK2TK1 | |
| SCHEMBL29414053 | 0.86 | RNASE1 (0.30) | RNASE1 | |
| SCHEMBL5954363 | 0.86 | TK2 (0.33) | RNASE1TK2TK1 | |
| SCHEMBL1705788 | 0.85 | ABCG2 (0.34) | TK2TK1 | |
| SCHEMBL6753657 | 0.84 | TK1 (0.38) | RNASE1TK2TK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 122 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-62201895-A | — | — | None | — | — | JP | disclosed |
| EP-4146280-A1 | LINKER COMPOUNDS | Mpeg LA, L.l.c. (US) | 2023-03-15 | — | — | EP | disclosed |
| EP-3647318-B1 | LINKAGE MODIFIED OLIGOMERIC COMPOUNDS | IONIS PHARMACEUTICALS INC (US) | 2021-06-30 | — | — | EP | disclosed |
| EP-3647318-A1 | LINKAGE MODIFIED OLIGOMERIC COMPOUNDS | Ionis Pharmaceuticals, Inc. (US) | 2020-05-06 | — | — | EP | disclosed |
| EP-3137476-B1 | LINKAGE MODIFIED OLIGOMERIC COMPOUNDS | IONIS PHARMACEUTICALS INC (US) | 2019-10-09 | — | — | EP | disclosed |
| US-10344275-B2 | Linkage modified oligomeric compounds | IONIS PHARMACEUTICALS, INC. (US) | 2019-07-09 | — | — | US | disclosed |
| US-20180305687-A1 | LINKAGE MODIFIED OLIGOMERIC COMPOUNDS | IONIS PHARMACEUTICALS, INC. (US) | 2018-10-25 | — | — | US | disclosed |
| US-9926556-B2 | Linkage modified oligomeric compounds | IONIS PHARMACEUTICALS, INC. (US) | 2018-03-27 | — | — | US | disclosed |
| CN-106661580-A | Antisense oligonucleotides for treating pompe disease | 鹿特丹伊拉斯谟大学医疗中心 | 2017-05-10 | — | — | CN | disclosed |
| EP-3137476-A1 | LINKAGE MODIFIED OLIGOMERIC COMPOUNDS | Ionis Pharmaceuticals, Inc. (US) | 2017-03-08 | — | — | EP | disclosed |
| WO-1992019637-A1 | OLIGONUCLEOTIDE ANALOGS CONTAINING THIOFORMACETAL LINKAGES | GILEAD SCIENCES, INC. (US) | 1992-11-12 | — | — | WO | disclosed |
| EP-0498843-A4 | OLIGONUCLEOTIDE ANALOGS WITH NOVEL LINKAGES | — | 1992-11-04 | — | — | EP | disclosed |
| EP-0498843-A1 | OLIGONUCLEOTIDE ANALOGS WITH NOVEL LINKAGES. | GILEAD SCIENCES INC (US) | 1992-08-19 | — | — | EP | disclosed |
| WO-1992004364-A1 | A METHOD OF LINKING NUCLEOSIDES WITH A SILOXANE BRIDGE | STERLING WINTHROP INC. (US) | 1992-03-19 | — | — | WO | disclosed |
| WO-1992002534-A2 | COMPOUNDS AND METHODS FOR INHIBITING GENE EXPRESSION | STERLING DRUG, INC. (US) | 1992-02-20 | — | — | WO | disclosed |
| WO-1991006629-A1 | OLIGONUCLEOTIDE ANALOGS WITH NOVEL LINKAGES | GILEAD SCIENCES, INC. (US) | 1991-05-16 | — | — | WO | disclosed |
| WO-1991004983-A1 | NUCLEOSIDE AND POLYNUCLEOTIDE THIOPHOSPHORAMIDITE AND PHOSPHORODITHIOATE COMPOUNDS AND PROCESSES | UNIVERSITY PATENTS, INC. (US) | 1991-04-18 | — | — | WO | disclosed |
| EP-0334694-A1 | Nucleic acid probes with non-radioactive labels, and preparation processes | LA REGION WALLONNE (BE) | 1989-09-27 | — | — | EP | disclosed |
| JP-S62201895-A | DEOXYNUCLEOSIDE PHOSPHORSULFIDE COMPOUND | TOAGOSEI CHEM IND CO LTD | 1987-09-05 | — | — | JP | disclosed |
| EP-0119621-A1 | Interleukin-2 | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1984-09-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180305687-A1 | LINKAGE MODIFIED OLIGOMERIC COMPOUNDS | PHAX, HNRNPM, HNRNPAB | RNASE1 50/4885TK2 376/4885TK1 209/4885 |
| US-10344275-B2 | Linkage modified oligomeric compounds | PHAX, HNRNPM, HNRNPAB | RNASE1 50/4885TK2 376/4885TK1 209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.